Guggenheim downgraded Arcturus Therapeutics (ARCT) to Neutral from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics Announces Phase 2 Trial Results
- Arcturus Therapeutics announces interim results from ARCT-032 trial
- Citi places ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
- Arcturus Therapeutics Partners on New COVID-19 Vaccine Launch
- Cathie Wood Scales Back Roku and Roblox Stakes, Boosts Arcturus Holding